XML 112 R97.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Collaborative Arrangements - Additional Information (Details) | 12 Months Ended
--- | ---
Dec. 31, 2024 USD ($) Agreement
VUMERITY |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
Percentage of net sales in royalty payment | 15.00%
License agreement | Janssen | 9 O-H Risperidone Palimate [Member] |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
Patent royalty rate (as a percent) | 1.50%
Know-how royalty rate resets (as a percent) | 3.50%
Period after the date of the first commercial sale of the product for license expiration | 15 years
License agreement | Janssen | 9 O-H Risperidone Palimate [Member] | Net sales of below $250.0 million |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
Know-how royalty rate (as a percent) | 3.50%
License agreement | Janssen | 9 O-H Risperidone Palimate [Member] | Net sales between $250.0 million and 500.0 million |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
Know-how royalty rate (as a percent) | 5.50%
License agreement | Janssen | 9 O-H Risperidone Palimate [Member] | Net sales greater than $500.0 million |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
Know-how royalty rate (as a percent) | 7.50%
License agreement | Janssen | 9 O-H Risperidone Palimate [Member] | Minimum | Net sales between $250.0 million and 500.0 million |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
Aggregate worldwide net sales | $ 250,000,000
License agreement | Janssen | 9 O-H Risperidone Palimate [Member] | Minimum | Net sales greater than $500.0 million |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
Aggregate worldwide net sales | 500,000,000
License agreement | Janssen | 9 O-H Risperidone Palimate [Member] | Maximum | Net sales of below $250.0 million |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
Aggregate worldwide net sales | 250,000,000
License agreement | Janssen | 9 O-H Risperidone Palimate [Member] | Maximum | Net sales between $250.0 million and 500.0 million |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
Aggregate worldwide net sales | $ 500,000,000
License agreement | Janssen | RISPERDAL CONSTA |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
Royalty rate (as a percent) | 2.50%
Period after the date of the first commercial sale of the product for license expiration | 15 years
Number of license agreements | Agreement | 2
Notice period required to be given before termination of agreement | 30 days
Period for resolving default or breach after the receipt of notice for termination of agreement | 90 days
Manufacturing and supply agreement | Janssen | RISPERDAL CONSTA |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
Period after the date of the first commercial sale of the product for license expiration | 60 days
Notice period required to be given before termination of agreement | 6 months
Manufacturing and supply agreement | Janssen | RISPERDAL CONSTA | Minimum |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
Royalty rate (as a percent) | 7.50%
Royalty rate upon termination of manufacturing and supply agreement (as a percent) | 2.50%
Manufacturing and supply agreement | Janssen | RISPERDAL CONSTA | Maximum |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
Royalty rate upon termination of manufacturing and supply agreement (as a percent) | 5.00%

X
- Definition Represents the notice period required to be served before the termination of the agreement. + References No definition available. + Details
Name: | alks_CollaborativeArrangementEffectiveNoticePeriodRequiredToBeServedForTerminationOfAgreement
Namespace Prefix: | alks_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the know-how patent royalty as a percentage of net sales under the collaborative agreements. + References No definition available. + Details
Name: | alks_CollaborativeArrangementKnowHowRoyaltyRate
Namespace Prefix: | alks_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative arrangement know how royalty rate resets. + References No definition available. + Details
Name: | alks_CollaborativeArrangementKnowHowRoyaltyRateResets
Namespace Prefix: | alks_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the aggregate worldwide net sales tied to know-how royalty under the collaborative agreements. + References No definition available. + Details
Name: | alks_CollaborativeArrangementNetSalesTiedToKnowHowRoyalty
Namespace Prefix: | alks_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the patent royalty as a percentage of net sales under the collaborative agreements. + References No definition available. + Details
Name: | alks_CollaborativeArrangementPatentRoyaltyRate
Namespace Prefix: | alks_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the period after the date of the first commercial sale of the product in a particular country that the agreement will expire. + References No definition available. + Details
Name: | alks_CollaborativeArrangementPeriodAfterDateOfFirstCommercialSaleOfProductForExpirationOfAgreement
Namespace Prefix: | alks_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the period for resolving default or breach after the receipt of notice for termination of agreement. + References No definition available. + Details
Name: | alks_CollaborativeArrangementPeriodForResolvingDefaultOrBreachAfterReceiptOfNoticeForTerminationOfAgreement
Namespace Prefix: | alks_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents royalty as a percentage of net sales under the collaborative agreements. + References No definition available. + Details
Name: | alks_CollaborativeArrangementRoyaltyRate
Namespace Prefix: | alks_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents royalty rate upon termination of related agreement. + References No definition available. + Details
Name: | alks_CollaborativeArrangementRoyaltyRateUponTerminationOfRelatedAgreement
Namespace Prefix: | alks_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of license agreements. + References No definition available. + Details
Name: | alks_NumberOfLicenseAgreements
Namespace Prefix: | alks_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of net sales in royalty payment. + References No definition available. + Details
Name: | alks_PercentageOfNetSalesInRoyaltyPayment
Namespace Prefix: | alks_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=alks_VumerityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=alks_LicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=alks_JanssenMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=alks_OHRisperidonePalimateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContractWithCustomerBasisOfPricingAxis=alks_NetSalesBelow250MillionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContractWithCustomerBasisOfPricingAxis=alks_NetSalesBetween250And500MillionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContractWithCustomerBasisOfPricingAxis=alks_NetSalesGreaterThan500MillionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=alks_RISPERDALCONSTAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=alks_ManufacturingAndSupplyAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |